Fourrts (india) Laboratories Private Limited

Fourrts (India) Laboratories Private Limited, established on March 31, 1979, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U85185TN1979PTC007782. As of the latest available data, Fourrts has an authorized share capital of ₹100 crore and a paid-up capital of ₹62.94 crore. The company is classified as a non-government company limited by shares.

Over the years, Fourrts has grown to become one of India's fastest-growing pharmaceutical companies, with a dedicated team of over 2,500 professionals. The company's products are available in more than 50 countries worldwide, reflecting its significant global presence.

Fourrts operates two state-of-the-art manufacturing facilities:

• Plant I: A WHO-GMP certified facility accredited by Bureau Veritas for ISO 9001:2015. This plant caters to emerging markets, with products present in over 40 countries. Its capabilities include the production of coated and uncoated tablets, capsules, liquid orals, creams, ointments, and medicated toothpaste.

• Plant II: A world-class facility approved by the US FDA, UK MHRA, EU GMP, Saudi FDA, Health Canada, and TGA Australia. With a production capacity of 4 billion tablets and 350 million capsules annually, Plant II specializes in contract manufacturing (CMO) and formulation development (CDMO) services.

The leadership team at Fourrts includes:

• Sekharipuram Viswanathan Veeramani: Managing Director since the company's inception in 1979.

• Veerramani Radha: Director since October 31, 1991.

• Mohan Lakshminarayan Iyer: Additional Director since December 15, 2021.

• Nitia Mohan: Additional Director since December 15, 2021.

• Gayatri Veeramani Jayaraman: Additional Director since December 15, 2021.

• Sundar Jayaraman: Additional Director since December 15, 2021.

Fourrts has established a strong presence in several regulated markets:

• United States: The company has a manufacturing facility approved by the US FDA, indicating compliance with stringent US regulatory standards.

• European Union: Fourrts' Plant II holds EU GMP certification, ensuring adherence to European manufacturing standards.

• United Kingdom: The company's manufacturing facility is approved by the UK MHRA, reflecting compliance with UK regulatory requirements.

• Australia: Fourrts' Plant II is approved by the TGA Australia, demonstrating adherence to Australian manufacturing standards.

These approvals facilitate Fourrts' market access and distribution in these regions.

Fourrts has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are present in over 40 countries, indicating a significant footprint in these regions.

Fourrts' geographic strategy involves a balanced approach, with a significant presence in both regulated and emerging markets. This diversification mitigates concentration risk and positions the company for sustained growth across diverse regions.

Fourrts' manufacturing facility is registered with the US FDA, indicating compliance with US regulatory standards.

The company holds WHO-GMP certification for Plant I and EU GMP certification for Plant II, ensuring adherence to international manufacturing standards.

Fourrts operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national pharmaceutical regulations.

As of the latest available data, there are no reported FDA Form 483 observations, warning letters, or import alerts associated with Fourrts.

In the analgesics and antipyretics category, Fourrts' top products include Metformin, Ibuprofen, Paracetamol, Cetirizine, and Naproxen. The company holds a 2.2% market share in Cetirizine, positioning it as a market leader in this segment.

Fourrts' key differentiators include its strong commitment to ethical practices, innovative product development, and adherence to high-quality manufacturing standards. The company's extensive experience and global presence further distinguish it in the pharmaceutical industry.

Fourrts' current strategic direction focuses on expanding its presence in both regulated and emerging markets, with a strong emphasis on contract manufacturing and formulation development services. The company's future outlook includes continued growth through innovation and adherence to international quality standards.

Fourrts has a robust track record in pharmaceutical manufacturing, with a significant export volume and consistency in product quality. The company's adherence to international regulatory standards and certifications indicates reliability and trustworthiness as a supplier.

Importers should verify the following certifications when considering Fourrts as a supplier:

• FDA Approval: Confirm the facility's registration with the US FDA.

• WHO-GMP Certification: Verify the WHO-GMP certification for Plant I.

• EU GMP Certification: Ensure the EU GMP certification for Plant II.

• ISO 9001:2015 Certification: Check the ISO 9001:2015 accreditation by Bureau Veritas.

These certifications can typically be verified through the respective regulatory bodies or the company's official communications.

When conducting due diligence on Fourrts, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's certifications and approvals from relevant regulatory bodies.

• Assess Financial Health: Review the company's financial statements and growth trajectory.

• Evaluate Product Portfolio: Analyze the range and quality of products offered.

• Check Compliance History: Investigate any past regulatory issues or compliance breaches.

• Assess Supply Chain Reliability: Evaluate the consistency and reliability of the company's supply chain operations.

Be cautious of any discrepancies in certifications or regulatory approvals, as these may indicate potential risks.